Trial Profile
Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 mg Once Daily With Food Versus Dolutegravir 50 mg Twice Daily in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 27 Feb 2023 Planned End Date changed from 30 Jun 2022 to 30 Jun 2024.
- 27 Feb 2023 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2024.
- 22 Mar 2022 Planned End Date changed from 30 Jun 2021 to 30 Jun 2022.